Results of Study to Evaluate Grail’s MCED Test Announced
The analysis showed strong performance of Grail’s MCED methylation-based platform in the symptomatic population of more than 6,000 patients
Read MorePosted by Melanie Hamilton-Basich | Jun 7, 2023 | Cancer |
The analysis showed strong performance of Grail’s MCED methylation-based platform in the symptomatic population of more than 6,000 patients
Read MorePosted by Melanie Hamilton-Basich | Jun 6, 2023 | Cancer, Sequencing Systems |
The study’s multi-cancer early detection data show Exai’s RNA- and AI-based platform can detect multiple cancer types at the earliest stages using a single, standard blood sample.
Read MorePosted by Chris Wolski | Jun 1, 2023 | Cancer |
Labcorp has launched Labcorp Plasma Focus, a new liquid biopsy test enabling targeted therapy selection for solid tumors.
Read MorePosted by Chris Wolski | Jun 1, 2023 | Molecular Diagnostics |
GT Molecular, Inc. is entering the cancer molecular assay market with multi-target PCR kits featuring quality control metrics.
Read MorePosted by Melanie Hamilton-Basich | May 30, 2023 | Lung Cancer |
The first-generation lung cancer classification model based on gene expression data is already available for use within Qlucore Insights.
Read More